Salarius Pharmaceuticals Inc Financials

SLRX

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Salarius Pharmaceuticals Inc (SLRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

Salarius Pharmaceuticals Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.81x

For every $1 of reported earnings, Salarius Pharmaceuticals Inc generates $0.81 in operating cash flow (-$4.5M OCF vs -$5.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Revenue

N/A

EBITDA

-$5.7M

YoY+55.5%

Salarius Pharmaceuticals Inc's EBITDA was -$5.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 55.5% from the prior year.

Free Cash Flow

N/A

Net Income

-$5.6M

YoY+55.5%

Salarius Pharmaceuticals Inc reported -$5.6M in net income in fiscal year 2024. This represents an increase of 55.5% from the prior year.

EPS (Diluted)

$-5.79

Salarius Pharmaceuticals Inc earned $-5.79 per diluted share (EPS) in fiscal year 2024. This represents an increase of 81.2% from the prior year.

Cash & Debt

$2.4M

YoY-58.7%

5Y CAGR-8.2%

Salarius Pharmaceuticals Inc held $2.4M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

96,077

Salarius Pharmaceuticals Inc had 96,077 shares outstanding in fiscal year 2024. This represents a decrease of 80.5% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$770K

YoY-89.3%

5Y CAGR-28.1%

Salarius Pharmaceuticals Inc invested $770K in research and development in fiscal year 2024. This represents a decrease of 89.3% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

SLRX Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	$0-100.0%	$1.8M-64.8%	$5.2M+51.0%	$3.5M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$770K-89.3%	$7.2M-54.7%	$15.8M+85.3%	$8.5M+23.6%	$6.9M+72.0%	$4.0M
SG&A Expenses	$5.0M-13.2%	$5.7M-19.9%	$7.1M+16.9%	$6.1M0.0%	$6.1M-20.8%	$7.7M
Operating Income	-$5.7M+55.5%	-$12.9M+59.5%	-$31.8M-148.5%	-$12.8M-64.6%	-$7.8M+5.8%	-$8.3M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	$0
Net Income	-$5.6M+55.5%	-$12.5M+60.3%	-$31.6M-147.6%	-$12.8M-73.7%	-$7.4M-6.0%	-$6.9M
EPS (Diluted)	$-5.79	$-30.74	$-14.88-92.7%	$-7.72	$-0.50	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q1'23	Q4'22	Q3'22	Q2'22
Revenue	N/A	N/A	N/A	N/A	$0	$0	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$62K-54.9%	$137K	N/A	$1.0M-72.2%	$3.7M-20.5%	$4.7M+23.6%	$3.8M+29.7%	$2.9M
SG&A Expenses	$833K-4.1%	$869K	N/A	$1.5M-11.8%	$1.7M-5.4%	$1.8M-2.2%	$1.8M-0.2%	$1.8M
Operating Income	-$895K+11.1%	-$1.0M	N/A	-$2.5M+53.3%	-$5.4M+16.3%	-$6.5M+55.3%	-$14.5M-204.5%	-$4.8M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$873K+10.1%	-$972K	N/A	-$2.4M+54.3%	-$5.3M+16.2%	-$6.4M+55.8%	-$14.4M-205.4%	-$4.7M
EPS (Diluted)	$-1.81	$-11.38	N/A	$-5.21-133.6%	$-2.23+24.9%	$-2.97+53.7%	$-6.41	$-2.20

SLRX Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$3.0M-54.1%	$6.6M-55.0%	$14.7M-64.1%	$40.8M+63.8%	$24.9M+79.4%	$13.9M
Current Assets	$3.0M-54.2%	$6.5M-55.1%	$14.5M-51.9%	$30.2M+90.9%	$15.8M+236.5%	$4.7M
Cash & Equivalents	$2.4M-58.7%	$5.9M-51.3%	$12.1M-58.6%	$29.2M+162.8%	$11.1M+197.4%	$3.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	$0-100.0%	$8.9M0.0%	$8.9M0.0%	$8.9M
Total Liabilities	$1.5M+16.3%	$1.3M-69.5%	$4.3M+102.1%	$2.1M-23.9%	$2.8M-16.3%	$3.3M
Current Liabilities	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$1.5M-71.4%	$5.3M-49.1%	$10.4M-73.2%	$38.7M+74.7%	$22.2M+109.4%	$10.6M
Retained Earnings	-$81.9M-7.3%	-$76.3M-19.7%	-$63.8M-98.2%	-$32.2M-65.7%	-$19.4M-60.9%	-$12.1M

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q1'23	Q4'22	Q3'22	Q2'22
Total Assets	$6.1M+101.7%	$3.0M-54.1%	$6.6M-21.6%	$8.4M-16.4%	$10.1M-31.4%	$14.7M-25.7%	$19.7M-41.4%	$33.7M
Current Assets	$6.1M+103.0%	$3.0M-54.2%	$6.5M-21.7%	$8.3M-16.3%	$9.9M-31.5%	$14.5M-19.2%	$18.0M-21.9%	$23.0M
Cash & Equivalents	$4.8M+97.6%	$2.4M-58.7%	$5.9M-22.2%	$7.6M-18.3%	$9.3M-23.4%	$12.1M-28.0%	$16.8M-25.7%	$22.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$8.9M
Total Liabilities	$1.8M+22.3%	$1.5M+16.3%	$1.3M-44.0%	$2.3M-48.4%	$4.5M+5.4%	$4.3M+37.2%	$3.1M+12.3%	$2.8M
Current Liabilities	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$4.2M+181.0%	$1.5M-71.4%	$5.3M-13.1%	$6.1M+9.4%	$5.6M-46.5%	$10.4M-37.5%	$16.6M-46.2%	$30.9M
Retained Earnings	-$85.5M-4.3%	-$81.9M-7.3%	-$76.3M-1.2%	-$75.5M-9.1%	-$69.1M-8.4%	-$63.8M-11.1%	-$57.4M-33.5%	-$43.0M

SLRX Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$4.5M+64.8%	-$12.8M+27.0%	-$17.6M-72.5%	-$10.2M+1.1%	-$10.3M+11.0%	-$11.6M
Capital Expenditures	N/A	N/A	N/A	$0-100.0%	$3K	$0
Free Cash Flow	N/A	N/A	N/A	-$10.2M+1.1%	-$10.3M+10.9%	-$11.6M
Investing Cash Flow	N/A	$0+100.0%	-$1.5M	$0+100.0%	-$3K-100.0%	$5.6M
Financing Cash Flow	$1.1M-84.0%	$6.6M+234.1%	$2.0M-93.0%	$28.3M+59.9%	$17.7M+394.3%	$3.6M
Dividends Paid	N/A	N/A	N/A	N/A	$0-100.0%	$134K
Share Buybacks	N/A	N/A	N/A	N/A	N/A	$0

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q1'23	Q4'22	Q3'22	Q2'22
Operating Cash Flow	-$1.6M-121.8%	-$743K+50.9%	-$1.5M+59.7%	-$3.7M-18.3%	-$3.2M+32.8%	-$4.7M+17.9%	-$5.7M-58.6%	-$3.6M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	$0	$0	$0	$0	$0	$0
Financing Cash Flow	$5.9M+5578.9%	-$107K+36.9%	-$169K+20.0%	-$212K-162.9%	$337K+33668100.0%	$1+100.0%	-$86K-104.1%	$2.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SLRX Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	-696.3%-547.5pp	-148.8%+89.8pp	-238.5%
Net Margin	N/A	N/A	N/A	-693.8%-553.4pp	-140.5%+59.7pp	-200.2%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-184.4%+6.0pp	-190.4%+25.3pp	-215.7%-184.5pp	-31.3%-1.8pp	-29.5%+20.4pp	-49.9%
Current Ratio	N/A	N/A	N/A	N/A	N/A	N/A
Debt-to-Equity	1.00+0.8	0.25-0.2	0.41+0.4	0.05-0.1	0.13-0.2	0.31
FCF Margin	N/A	N/A	N/A	-554.3%-357.2pp	-197.1%+137.1pp	-334.2%

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q1'23	Q4'22	Q3'22	Q2'22
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-14.3%+10.9pp	-25.2%	N/A	-29.1%+24.0pp	-53.1%-9.6pp	-43.5%+29.6pp	-73.1%-59.0pp	-14.0%
Current Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Debt-to-Equity	0.44-0.6	1.00+0.8	0.25-0.1	0.38-0.4	0.81+0.4	0.41+0.2	0.19+0.1	0.09
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Gt Biopharma Inc GTBP

$12.4M

Protagenic Therapeutics Inc PTIX

$1.4M

Lipella Pharmaceuticals Inc LIPO

$11.8M

Indaptus Therapeutics Inc INDP

$3.9M

Scinai Immunotherapeutics Ltd. SCNI

$2.6M

Frequently Asked Questions

Is Salarius Pharmaceuticals Inc profitable?

No, Salarius Pharmaceuticals Inc (SLRX) reported a net income of -$5.6M in fiscal year 2024.

What is Salarius Pharmaceuticals Inc's earnings per share (EPS)?

Salarius Pharmaceuticals Inc (SLRX) reported diluted earnings per share of $-5.79 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Salarius Pharmaceuticals Inc's EBITDA?

Salarius Pharmaceuticals Inc (SLRX) had EBITDA of -$5.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Salarius Pharmaceuticals Inc's operating cash flow?

Salarius Pharmaceuticals Inc (SLRX) generated -$4.5M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Salarius Pharmaceuticals Inc's total assets?

Salarius Pharmaceuticals Inc (SLRX) had $3.0M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Salarius Pharmaceuticals Inc spend on research and development?

Salarius Pharmaceuticals Inc (SLRX) invested $770K in research and development during fiscal year 2024.

How many shares does Salarius Pharmaceuticals Inc have outstanding?

Salarius Pharmaceuticals Inc (SLRX) had 96,077 shares outstanding as of fiscal year 2024.

What is Salarius Pharmaceuticals Inc's debt-to-equity ratio?

Salarius Pharmaceuticals Inc (SLRX) had a debt-to-equity ratio of 1.00 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Salarius Pharmaceuticals Inc's return on assets (ROA)?

Salarius Pharmaceuticals Inc (SLRX) had a return on assets of -184.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Salarius Pharmaceuticals Inc's cash runway?

Based on fiscal year 2024 data, Salarius Pharmaceuticals Inc (SLRX) had $2.4M in cash against an annual operating cash burn of $4.5M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Salarius Pharmaceuticals Inc's Piotroski F-Score?

Salarius Pharmaceuticals Inc (SLRX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Salarius Pharmaceuticals Inc's earnings high quality?

Salarius Pharmaceuticals Inc (SLRX) has an earnings quality ratio of 0.81x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.